A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-18
DOI
10.3389/fphar.2020.00686
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Therapeutic Potential of Nanobodies
- (2019) Ivana Jovčevska et al. BIODRUGS
- Comparative analysis of nanobody sequence and structure data
- (2018) Laura S. Mitchell et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
- (2018) Meike Hutt et al. Oncotarget
- IgG-single-chain TRAIL fusion proteins for tumour therapy
- (2018) Martin Siegemund et al. Scientific Reports
- The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
- (2017) Torsten Hartwig et al. MOLECULAR CELL
- The involvement of Eag1 potassium channels and miR-34a in rotenone-induced death of dopaminergic SH-SY5Y cells
- (2017) Camila Hillesheim Horst et al. Molecular Medicine Reports
- Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors
- (2017) Yanni Zhu et al. Scientific Reports
- Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
- (2017) Katerina T. Xenaki et al. Frontiers in Immunology
- Cullin 7 mediates proteasomal and lysosomal degradations of rat Eag1 potassium channels
- (2017) Po-Hao Hsu et al. Scientific Reports
- Periodic expression of Kv10.1 driven by pRb/E2F1 contributes to G2/M progression of cancer and non-transformed cells
- (2016) Diana Urrego et al. CELL CYCLE
- Cyclic expression of the voltage‐gated potassium channel KV10.1 promotes disassembly of the primary cilium
- (2016) Araceli Sánchez et al. EMBO REPORTS
- Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin
- (2016) Franziska Hartung et al. EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS
- ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation
- (2016) Jinwoo Leem et al. mAbs
- Kv10.1 K+ channel: from physiology to cancer
- (2016) Halima Ouadid-Ahidouch et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival
- (2015) Ramón Martínez et al. BMC CANCER
- Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis
- (2015) Silvia von Karstedt et al. CANCER CELL
- Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC
- (2015) María de Guadalupe Chávez-López et al. TUMOR BIOLOGY
- Positive correlation between the expression of hEag1 and HIF-1α in breast cancers: an observational study
- (2014) Qingxuan Lai et al. BMJ Open
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells
- (2013) Dong-Hui Zhou et al. Hepatobiliary & Pancreatic Diseases International
- MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether à go-go 1 Expression
- (2013) Xinyu Wu et al. International Journal of Medical Sciences
- Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties
- (2013) O. Seifert et al. MOLECULAR CANCER THERAPEUTICS
- MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1)
- (2012) Yifeng Bai et al. EUROPEAN JOURNAL OF CANCER
- Frequent aberrant expression of the human ether à go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications
- (2012) Sofía Tirados Menéndez et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody
- (2011) Franziska Hartung et al. Molecular Cancer
- Correction: Transcriptional and Post-Transcriptional Mechanisms for Oncogenic Overexpression of Ether À Go-Go K+Channel
- (2011) Huixian Lin et al. PLoS One
- Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen
- (2009) Ghislaine Behar et al. FEBS Journal
- Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors
- (2008) Bryan R. Downie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
- (2008) Edwin Bremer et al. JOURNAL OF MOLECULAR MEDICINE-JMM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started